Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen V Liu

Showing results (1-10 of 187) with videos related to

Pageof 19
Sort By:
Clinical Advances in Hematology & Oncology : H&O|July 8, 2022
Novel targets in advanced non-small cell lung cancerStephen V Liu
Future Oncology (London, England)|July 25, 2022
Plain language summary of NRG1 fusions in cancer: current knowledge and treatment with afatinib and other drugsStephen V Liu
Lung Cancer (Amsterdam, Netherlands)|June 7, 2021
NRG1 fusions: Biology to therapyStephen V Liu
Therapeutic Advances in Medical Oncology|January 8, 2021
Chemo-immunotherapy as first-line treatment for small-cell lung cancerSaira Farid, Stephen V Liu
Annals of Translational Medicine|October 3, 2019
Combining immunotherapy and epidermal growth factor receptor kinase inhibitors: worth the risk?Hira Latif, Stephen V Liu
The New England Journal of Medicine|February 28, 2019
Atezolizumab plus Chemotherapy in Small-Cell Lung Cancer. ReplyLeora Horn, Stephen V Liu
Translational Lung Cancer Research|November 19, 2020
Novel <i>ALK</i> mutation with durable response to brigatinib-a case reportHira Latif, Stephen V Liu
Med (New York, N.Y.)|November 9, 2024
ADRIATIC: When face value is enoughAlfredo Addeo, Stephen V Liu
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 24, 2023
Zipalertinib in <i>EGFR</i> Exon 20-Mutant Non-Small-Cell Lung Cancer: Drug Development in a Rare but Crowded SettingCharu Aggarwal, Stephen V Liu
Nature Reviews. Clinical Oncology|January 22, 2014
Lung cancer in 2013: Refining standard practice and admitting uncertaintyStephen V Liu, Giuseppe Giaccone
Pageof 19

Showing results (1-10 of 187) with videos related to

Sort By:
Pageof 19
Clinical Advances in Hematology & Oncology : H&O|July 8, 2022
Novel targets in advanced non-small cell lung cancerStephen V Liu
Future Oncology (London, England)|July 25, 2022
Plain language summary of NRG1 fusions in cancer: current knowledge and treatment with afatinib and other drugsStephen V Liu
Lung Cancer (Amsterdam, Netherlands)|June 7, 2021
NRG1 fusions: Biology to therapyStephen V Liu
Therapeutic Advances in Medical Oncology|January 8, 2021
Chemo-immunotherapy as first-line treatment for small-cell lung cancerSaira Farid, Stephen V Liu
Annals of Translational Medicine|October 3, 2019
Combining immunotherapy and epidermal growth factor receptor kinase inhibitors: worth the risk?Hira Latif, Stephen V Liu
The New England Journal of Medicine|February 28, 2019
Atezolizumab plus Chemotherapy in Small-Cell Lung Cancer. ReplyLeora Horn, Stephen V Liu
Translational Lung Cancer Research|November 19, 2020
Novel <i>ALK</i> mutation with durable response to brigatinib-a case reportHira Latif, Stephen V Liu
Med (New York, N.Y.)|November 9, 2024
ADRIATIC: When face value is enoughAlfredo Addeo, Stephen V Liu
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 24, 2023
Zipalertinib in <i>EGFR</i> Exon 20-Mutant Non-Small-Cell Lung Cancer: Drug Development in a Rare but Crowded SettingCharu Aggarwal, Stephen V Liu
Nature Reviews. Clinical Oncology|January 22, 2014
Lung cancer in 2013: Refining standard practice and admitting uncertaintyStephen V Liu, Giuseppe Giaccone
Pageof 19